For RA, investigation from Jin et al. targeting 13,210 Chinese RA patients identified malignancy as one of the major comorbidities of RA with a prevalence of 0.6% at baseline, and MTX usage was negatively associated with malignancy (HR = 0.57, p = 0.02) (8), while Solomon et al. showed that cancer risk was elevated for methotrexate users compared with other nbDMARDs and TNF antagonists (9). Here, TNF is linked to cancer.